

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



FSU

The Patent Office



INVESTOR IN PEOPLE

9300/303

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 25 FEB 2000

WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.


PRIORITY DOCUMENT


SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Signed

Dated

17 FEB 2000





Patent Office

05 FEB 1999 12:51:01 C03073
P01/7700 0.00 - 9902527.2

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference

RJG/JLB/2859

n 4 FEB 1999

2. Patent application number

(The Patent Office will fill in this part)

9902527.2

3. Full name, address and postcode of the or of each applicant (underline all surnames)

Phares Pharmaceutical Research NV
14 John B Gorsiraweg
PO Box 3889
Curacao
Netherlands Antilles

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

Netherlands Antilles

5830/20002

4. Title of the invention

Compositions

5. Name of your agent (if you have one)

Stevens, Hewlett & Perkins

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

1 Serjeants' Inn
Fleet Street
London EC4Y 1NT

Patents ADP number (if you know it)

1545003

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d))

Yes

- Patents Form 1/77**
9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form

Description 13

Claim(s) 2

Abstract

Drawing(s) 3 43

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)

Any other documents
(please specify).

11.

I/We request the grant of a patent on the basis of this application.

Signature

Date 4.2.99

AGENTS FOR THE APPLICANT

12. Name and daytime telephone number of person to contact in the United Kingdom

Robert J Gaunt 0171-936 2499

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Compositions

Field of the invention

- 5 The present invention relates to membrane lipid compositions. More specifically, it relates to powder complexes and compositions comprising phospholipid and one or more biologically active compounds, such as a xanthine and/or a salicylate.
- 10 Powder compositions of the invention have the unique property to form dispersions comprising structured lipid assemblies (SLAs) suspended in a solution of the active compound. The compositions may be used to deliver the biologically active compound, such as a xanthine and/or a salicylate, to the deeper layers of the skin, more effectively and efficiently, with reduced
- 15 irritation. By stabilising the active compounds in solution without solvents and strong surfactants, the invention is an improvement on prior art preparations containing xanthine and/or salicylate. The compositions of this invention are employed in lotions, sprays and creams, etc in skin care and other applications.

20

Background to the invention

- Cellulite is a fatty substance produced by fat cells (adipocytes) and deposited mainly under the thighs and buttocks which gives the skin an
- 25 "orange peel" appearance. Two competing processes involving breakdown (lypolysis) and production (lypogenesis) of fat occur in the cells. In lypolysis, triglycerides are converted into free fatty acids and glycerol by the action of triglyceride lipases. This reaction is activated by cyclic AMP which converts the lipases into active forms. Lypolysis is controlled by
- 30 phosphodiesterase, an enzyme which breaks down cyclic AMP and effectively prevents lypolysis. Xanthines, such as caffeine, theobromine

and theophylline can inhibit phosphodiesterase and thereby promote lipolysis. These compounds are reported to be active topically and can also temporarily dehydrate cells, making the skin look and feel firmer. Not surprisingly, xanthines are used widely in skin care products and slimming aids to prevent cellulite from accumulating.

Caffeine is a methylxanthine which is a CNS stimulant and inhibitor of phosphodiesterase. It is a white crystalline solid, soluble 1:10 in hot water, but crystallises as fine needles on cooling. It is sparingly soluble in fixed oils and ethanol. The solubility in cold water is approximately 1:50. However it is soluble 1:10 in equal parts of ethanol and water. Topical preparations containing caffeine are commonly used in anti-cellulite treatments. The preparations are either hydro-alcoholic solution/gel or cream/lotion type products. There are problems relating to irritancy or reduced efficacy with both of these types of formulations. An effective amount of caffeine cannot be kept in solution without using large amounts of ethanol. If a large amount of ethanol is used, the solution dries rapidly, leaving a white powder on the skin after application. Creams and lotions are more cosmetically acceptable, but they are perceived to be less effective because of the smaller amount of caffeine that can be solubilised. Therefore there is a need for an aesthetic and cosmetically acceptable preparation containing an effective amount of caffeine which does not crystallise out, is non-irritant and does not dry out the skin.

Salicylic acid is used in topical applications as an exfoliating agent and to remove wrinkles from under the eyes, in low concentrations(<0.2%), often as alkali salt. It is soluble in ethanol but only sparingly soluble in water. Salicylates, and in particular, salicylic acid is a skin irritant and it is usually combined with emollients in skin care products.

In this specification, the term phospholipid refers to at least one membrane

lipid or, preferably, a mixture of membrane lipids comprising phosphatidyl choline (PC), phosphatidyl ethanolamine (PE), phosphatidyl inositol (PI), phosphatidic acid (PI) and/or phosphatidyl serine (PS). The definition includes diacyl phospholipids and their monoacyl equivalents, with either
5 unsaturated or saturated hydrocarbon chain(s). Phospholipids are the most common examples of natural membrane lipids. They are the natural building blocks of cell membranes. Membrane lipids are essential for normal skin function. They protect the skin from irritants and alleviate the irritation. Therefore membrane lipids are commonly used in skin care
10 preparations to confer emollient and protective functions and to control transepidermal water loss. Most commonly, they are used to form liposomes designed to carry active compounds. Liposomes are made up of one or more alternating bilayers which can sequester both oil soluble and water soluble compounds. Liposomes have poor long term storage
15 stability, and therefore there are serious limitations in utilising liposomes to carry active compounds.

The present invention does not depend on liposome structure to entrap the active compound. It is not concerned with formation of liposomes, or with
20 liposome entrapment. The compositions simply utilise phospholipids, particularly mixtures of diacyl and monoacyl phospholipids, to prepare easily dispersible powder compositions that form small structured lipid assemblies (SLAs) on contact with water. The SLAs may be vesicles, micelles, mixed micelles or often a heterogeneous mixture, depending on
25 the types of phospholipid used. Typically, the SLAs have a diameter of between 0.05μ to 1μ (i.e. from 50nm to 1000nm). Surprisingly, it has been found that SLAs offer a valuable and effective source of natural membrane lipids that is convenient and easy to assimilate into the skin structure. The fact that the SLAs can also transport dissolved biologically active
30 compounds is an unexpected bonus.

On p1651 of the 31st edition of Martindale The Extra Pharmacopoeia, it is disclosed that caffeine can be dissolved in concentrated solutions of alkali benzoates and salicylates. Caffeine is used orally in medicine as a CNS stimulant. It is also included in analgesics as the free base or as a water-soluble (e.g. citrate) salt. However, in skin care applications, the free base is mostly preferred due to its lipophilic properties.

There are many known caffeine preparations for anti-cellulite treatment. These contain a maximum of about 5% caffeine dissolved in ethanol or incorporated in the form of caffeine benzoate in creams and lotions.

PCT application WO 95/34279 describes aqueous liposomal dispersions of phospholipids comprising a carboxylic acid or salicylic acid in the salt form that claim to be non-irritant and have skin beneficial properties. It would appear, from the examples disclosed, that the liposome suspensions are made from a pro-liposome composition disclosed in EP 0 158 441 B1.

Summary of the invention

The object of the present invention is two fold. Firstly, to provide a novel dry powder composition comprising at least one membrane lipid (e.g. phospholipid) with at least one biologically active compound (such as a xanthine, e.g. caffeine, and/or a carboxylic acid, e.g. alkali salicylate/salicylic acid), and which forms structured lipid assemblies (SLAs) when dispersed/dissolved in an aqueous medium, such as water. Secondly, to provide a stable dispersion of SLAs *in situ*, suspended in a solution of the biologically active compound(s). The dispersion may be made by using either the dry powder complex or by incorporating (dispersing/dissolving) the components thereof individually in water or other aqueous medium. Creams, gels, lotions, sprays and other preparations formulated for topical administration may be prepared from the dispersion or suspension accordingly.

In the compositions of this invention which contain them both, the efficacy of caffeine is enhanced because it is in molecular solution with the salicylate. Most importantly, the invention harnesses the properties of phospholipids to improve the bioavailability and reduce the irritancy of biologically active compounds, in a physically stable complex. Furthermore, the method of this invention avoids the use of solvents or harsh surfactants which can irritate and damage the skin. This represents a significant improvement on prior art preparations containing a xanthine and/or a carboxylic acid. Compositions comprising phospholipid, caffeine and/or salicylate in a dry powder complex have not been disclosed in the prior art.

Description of preferred embodiments

A preferred embodiment of the invention is a powder composition comprising the components in a homogeneous mixture. The preferred xanthine is caffeine as the free base, but other xanthines such as aminophylline, theophylline and theobromine may also be used. The proportion of caffeine in the powder complex is preferably between 10% to 80%, more preferably between 40% to 70%, by weight.

Sodium salicylate/salicylic acid, a β -hydroxycarboxylic acid, is the preferred carboxylic acid but other alkali salicylates or benzoates may be used. Benzoates tend to be more sensitising and should therefore be used with caution. The amount of sodium salicylate by weight in the powder mixture is preferably between 10% to 50%, more preferably between 20% to 40%. In addition to or in place of salicylates, α -hydroxycarboxylic acids, e.g. glycollic acid, lactic acid, citric acid, tartaric acid, maleic acid or mandelic acid, and/or α -ketocarboxylic acids, e.g. pyruvic acid, including their salt forms may be used in about the same proportions, i.e. about 10% to about 50% by weight, with the pH of the final preparation adjusted to between pH

5 to 7.5, so as to give maximum performance and minimum irritancy. The α -hydroxy carboxylic acids are found in fruit extracts and are known as "fruit acids". They are commonly used in anti-wrinkle preparations due to their keratolytic and anti-oxidant properties. It will be understood that the products of this invention may contain one, two, three or more biologically active compounds.

In another preferred embodiment of the invention, in place of caffeine at least one carboxylic acid or salt, eg, salicylate, is used in combination with the lipid to counteract the irritant potential of the fruit acids. These compositions are particularly suitable in anti-wrinkle skin care preparations. Where only two components, e.g. phospholipid and one carboxylic acid or acid salt, are present in the powder composition, the weight-ratio of lipid to biologically active compound is 20:1 to 1:20, preferably 10:1 to 5:1, with the proviso that there is sufficient lipid in the powder mixture to yield SLAs, when the powder mixture is dispersed in water at about 60°C.

The second essential component is a membrane lipid, and this may include natural, hydrogenated and synthetic phospholipids, glycolipids and polyglycerol esters. Blends of diacyl or monoacyl phospholipid available commercially as lecithin and enzyme hydrolysed lecithin, with a total phospholipid content of at least 60%, are preferred. Diacyl phospholipids, e.g. PC, tend to form SLAs which may be bilayered lamellae structures with an average diameter of about 1 μ in water, whilst monoacyl phospholipids (MAPC) form micelles that are about 50nm average diameter. Mixed micelle systems are formed by combinations of PC and MAPC and the average particle size is somewhere in between the diameters quoted above. Most preferably, the phospholipids are in particulate or granular form. The quantity of lipid in the dry powder mixture varies between 5% to 70%, most preferably between 10% to 50%. A combination of unsaturated lipid with low phase transition temperature (T_c) and hydrogenated lipid with

higher Tc is preferred to obtain complexes with optimum properties.

There are several benefits in using phospholipids in the invention. In skin care products, they can replace natural lipid and function as natural moisturisers, counteract the dehydrating effect of caffeine, and alleviate the irritant potential of the fruit acids. Phospholipids are also known to increase the bioavailability of biologically active compounds. Furthermore, phospholipids stabilise the formulations, preventing any mild crystal growth of e.g. caffeine, if the preparations are stored at low temperatures. This effect can be seen when two formulations are prepared, one containing a high level of caffeine without lipid, the other containing caffeine and lipid complex. When stored at 4°C, crystals develop much faster in the preparation without lipid. Phospholipids are natural emulsifiers and can help stabilise up to 40% of an oil and thereby reduce the amount of ethoxylated emulsifiers. A further advantage of the invention is that the phospholipid helps to bind and prevent segregation of the components in the powder mixture, particularly during storage and transport.

The powder compositions may be prepared by dissolving/dispersing all the components in a suitable solvent, e.g. ethanol, aqueous ethanol solutions or chloroform and removing the solvent to obtain a solid complex that can be pulverised. Alternatively, all the components may be simply mixed or milled together to obtain a homogeneous and uniform powder mixture. This offers a convenient and efficient means to utilise caffeine and/or salicylate in a form which can be incorporated into different types of formulations. The powder mixture is simply added to water or other aqueous medium to obtain, *in situ*, a soluble caffeine and/or salicylate complex in a dispersion of lipid particles, free from ethanol. The suspension may be used as a sprayable lotion or it may be used to prepare creams and lotions that can additionally contain up to 40% of an oil.

The lipid-caffeine powder complex is a homogeneous composition with a mean particle size between 0.1 μ m to about 5 μ m in diameter. Preferably, the mean diameter is about 200 μ m to 500 μ m. The compositions have good storage stability and can be kept for extended periods until
5 required.

In a further embodiment of the invention, the individual components, namely phospholipid and the biologically active compound(s) e.g. caffeine and/or salicylate, are added separately in pre-weighed amounts, to water or
10 other aqueous medium. The resulting dispersion of SLAs can be used in the preparation of a cream or a lotion. The order is not critical, although preferably, the salicylate should be added first, followed by the caffeine or other xanthine. The lipid, which should preferably be in particulate form, is added last to the solution, with stirring, at an elevated temperature below
15 about 60°C. The phospholipids additionally help to keep the caffeine/salicylate in solution, most likely in a molecular complex. The mole ratio of caffeine to salicylate in the solution is between 1:1 to 1:4, preferably about 1:2. There is no strict limit to the ratio of caffeine to lipid, but preferably it should lie within the range 20:1 to 1:20, preferably 10:1 to
20 5:1.

The invention will be further described in the following examples. All percentages are by weight unless otherwise indicated.

25 Example 1

| | |
|--------------------------|--------|
| Caffeine | 52.6 % |
| Salicylic acid (Na salt) | 26.3 % |
| *Phospholipid | 21.1 % |

30

* Mixture of suitable lipid blends, containing a minimum of 60% total phospholipids

comprising PC, PE, PA, PI, and glycolipids in particulate form. In the above example the lipid blend was made up of a 1:2 mixture of hydrogenated and unsaturated lipids.

Method: 500 gm of the lipid-caffeine powder complex was prepared in the laboratory by grinding all the components in a mortar and pestle until a homogeneous and uniform powder composition was obtained. One gm of the powder composition dispersed in 10ml of water at 60°C to yield a solution of caffeine and SLAs in suspension, comprising vesicular structures of about 1 μ Z average diameter, as seen in the accompanying electron micrograph of Fig 1A.

Example 2

| | |
|---------------------------------|--------|
| Caffeine | 58.8 % |
| Salicylic acid (Na salt) | 29.4 % |
| *Phospholipid | 11.8 % |
| *Similar blend as in Example 1. | |

10 gm of the components was dissolved in 90% ethanol at about 50°C in a closed container. The ethanol was evaporated off to obtain a hard powder lump which could be comminuted to a free flowing powder of about 500 micron average diameter.

Example 3

| | |
|--|--------|
| Caffeine | 64.8 % |
| Salicylic acid (Na salt) | 24.9% |
| *Phospholipid | 10.3 % |
| *Enzyme modified lecithin containing about 65% MAPC and 15%PC. | |

10 kg of the lipid-caffeine powder complex was prepared by coarse mixing, followed by size reduction through a screen in a hammer mill, to obtain a free flowing uniform powder composition. Alternatively, the three

components could have been dissolved in ethanol-water solution and dried to a powder. One gm of the powder dispersed in 10 ml of warm water to give a clear micellar solution of caffeine and SLAs, as seen in the electron micrograph of Fig 1B (where no vesicular structures can be discerned).

5

Example 4

| | |
|--------------------------|--------|
| Salicylic acid (Na salt) | 50.0 % |
| *Phospholipid | 50.0 % |

10

*Hydrogenated lipid containing about 60% of total phospholipids and glycolipids.

The two components were co-milled to obtain a free flowing uniform lipid-salicylate powder composition that readily disperses in water at about 60°C with minimum agitation, to form a homogeneous dispersion of discrete SLAs and dissolved salicylate. In place of salicylate, one or more alpha hydroxycarboxylic acids (AHA) e.g. citric acid or maleic acid or their salt forms may be used.

20 The invention also relates to the use of the aforementioned lipid powder compositions for preparing suspensions, lotions and creams containing caffeine and/or a carboxylic acid/salt. Typical examples of the preparations are further described below.

25 Example 5

The lipid-caffeine powder from Example 1 was used to prepare an oil in water (o/w) cream.

30 **Lipid-caffeine complex 7%**

| | |
|------------------|--------|
| Emulgade SEV | 5% w/w |
| Cetyl alcohol | 2% |
| Dicaprylyl ether | 4% |
| Oleyl erucate | 1% |

| | | |
|---|----------------|---------|
| | Decyl oleate | 2% |
| | Cocoglycerides | 3% |
| | Glycerol | 3% |
| | Preservative | 0.2% |
| 5 | Fragrance | 0.2% |
| | Water | ad 100% |

The emulsifier (Emulgade) was obtained from Henkel. The lipid-caffeine powder from Example 1 was dispersed in about half the total amount of water at about 60°C. The emulsifier and waxes were melted in the mixture of oils heated to about 65°C and added to the aqueous suspension of caffeine, with stirring to form a cream. The rest of the water at 60°C was added to obtain an o/w lipid-caffeine cream. The cream was homogenised and cooled to room temperature. It was packed into jars. After storage for 30 days at 0°C and 45°C, the cream was examined at room temperature, for crystal growth. No crystals can be seen under a light microscope (at magnification of about x100), as shown in Fig 2A (which shows a sample of the cream according to this example after storage at 0°C for 30 days). Fig 2B shows a sample of a cream prepared as a control (containing caffeine but no lipid) after storage at 0°C for 30 days; crystals have clearly developed.

Example 6

- 25 The lipid-caffeine powder complex from Example 2 was used to prepare the gel formulation in this example.

| | | |
|----|-------------------------------|------|
| | Lipid-caffeine complex | 6% |
| | Glycerol | 3% |
| 30 | Carbopol 940 | 0.4% |
| | Permulant TR-1 | 0.2% |

| | | |
|---|--------------------|---------|
| | Cetearyl isononate | 3% |
| | Tocopherol acetate | 0.05% |
| | Preservative | 0.2% |
| | Fragrance | 0.2% |
| 5 | Water | ad 100% |

The Carbopol (a gelling agent) and Permulant (a thickener) were hydrated and dissolved in about half quantity of water at about 60°C, with high speed stirring, to obtain a lump free solution. The rest of the ingredients, except for the lipid-caffeine complex and the fragrance, were added. The lipid-caffeine complex was dispersed in the rest of the water at about 65°C to form a homogeneous lipid suspension and added to the Carbopol solution. The suspension was adjusted to pH 6.5 -7.0 to obtain a gel preparation comprising discrete SLAs and solubilised caffeine.

15

Example 7

This is an example of a simple lotion containing SLAs and solubilised caffeine prepared from the lipid-caffeine complex according to Example 3.

20

| | | |
|--|-------------------------------|---------|
| | Lipid-caffeine complex | 8% |
| | Preservative | 0.2% |
| | Fragrance | 0.2% |
| | Water | ad 100% |

25

The lipid-caffeine powder was added to water at ambient temperature containing the preservative, with mild agitation. A totally transparent micellar solution of SLAs with Z average diameter of below about 60nm was obtained using a Malvern autosizer. The fragrance was added last.

30

In place of the lipid-caffeine complex from Example 3, two gm of the lipid-

salicylate complex from Example 4 was added to the water containing the preservative at about 65°C, with agitation, to prepare a translucent lotion containing SLAs suspended in caffeine solution. The fragrance was added at room temperature. The Z average particle diameter of the SLAs was
5 about 1 μ , using a Malvern autosizer laser.

The powder complexes in Examples 1 to 4 are typical examples. Similar powder complexes may be prepared by using different blends of phospholipids and other xanthines and carboxylic acids. Alternatively, the
10 xanthine may be omitted and a powder complex comprising phospholipid and one or more fruit acids or one or more α -ketocarboxylic acids may be obtained using similar methods. In this case, the amount of fruit acid used in the powder mixture may vary from 10% to 50% by weight. The resultant powder compositions may be formulated into creams and lotions which are
15 typically shown in Examples 5 to 7.

CLAIMS

1. A composition in the form of a dry powder and which comprises:
 - 5 a) at least one membrane lipid, and
 - b) at least one biologically active compound,and which forms structured lipid assemblies when dispersed/dissolved in an aqueous medium.
- 10 2. A composition as claimed in claim 1, wherein said membrane lipid comprises a phospholipid or mixture of phospholipids.
3. A composition as claimed in claim 1 or claim 2, wherein said biologically active compound comprises a xanthine and/or a carboxylic
15 acid.
4. A composition as claimed in any one of the preceding claims, wherein said biologically active compound comprises an α -hydroxycarboxylic acid, a β -hydroxycarboxylic acid and/or an
20 α -ketocarboxylic acid.
5. A composition as claimed in any one of the preceding claims, wherein said biologically active compound is caffeine and/or salicylate or pharmaceutically acceptable salts thereof.
25
6. A composition as claimed in any one of the preceding claims, wherein the proportion of said membrane lipid to said biologically active compound is from 1:20 to 20:1 by weight.
- 30 7. A method of preparing a composition as claimed in any one of the preceding claims, which comprises either mixing or milling together the

components to produce a homogeneous dry powder, or
dispersing/dissolving the components, either sequentially or
simultaneously, in a solvent, subsequently removing the said solvent so as
to form a solid mixture and then pulverising the said solid mixture to
5 produce a homogeneous dry powder.

8. A dispersion of structured lipid assemblies suspended in a
solution of at least one biologically active compound.

10 9. A method of preparing a dispersion of structured lipid
assemblies as claimed in claim 8, which comprises dispersing/dissolving a
dry powder composition as claimed in any one of claims 1 to 7, or the
components of such a composition, with the said components being
dispersed or dissolved either sequentially or simultaneously, in an aqueous
15 medium.

10. A dispersion as claimed in claim 8 or as prepared by the
method of claim 9, and which is in the form of a cream, gel or lotion
formulated for topical administration.




FIG. 1A



FIG. 1B




FIG. 2A




FIG. 2B

PCT/GB001: 303

Stevens, Hewlett & Perkins

312100